ERBB2 and breast cancer: In 2022, the FDA expanded the indications of the approval of the PATHWAY anti-Her2/neu (4B5) rabbit monoclonal primary antibody (Ventana Medical Systems, Inc.)to include HER2 protein testing for patients with BC who may benefit from treatment with T-DXd [93].